Atara Biotherapeutics, INC. (ATRA) SEC Filings — 2025

Filings

• Atara Swings to Profit YTD, But Cash Dwindles Amid Revenue Dip — 10-Q · Nov 12, 2025
• Atara Biotherapeutics Reports Exit/Disposal Costs — 8-K · Oct 7, 2025
• Atara Biotherapeutics Announces Executive and Director Changes — 8-K · Sep 4, 2025
• Atara Narrows Losses to $58.1M Amid R&D Cuts, Cash Dwindles — 10-Q · Aug 11, 2025
• Atara Biotherapeutics Files 8-K: Operations & Financial Update — 8-K · Jul 14, 2025
• Atara Biotherapeutics Holds Special Stockholder Meeting — 8-K · Jun 11, 2025
• Atara Biotherapeutics Files 8-K Report — 8-K · May 16, 2025
• Atara Biotherapeutics Files 8-K on Leadership and Compensation — 8-K · May 15, 2025
• Atara Biotherapeutics Files Q1 2025 10-Q — 10-Q · May 15, 2025
• Atara Biotherapeutics Reports Exit/Disposal Costs — 8-K · May 12, 2025
• Atara Biotherapeutics Files 8-K — 8-K · May 6, 2025
• Atara Biotherapeutics Executive Compensation Details — DEF 14A · Apr 28, 2025
• Atara Biotherapeutics Enters Material Definitive Agreement — 8-K · Apr 4, 2025
• Atara Biotherapeutics Files 8-K: Director Changes & Officer Compensation Updates — 8-K · Mar 31, 2025
• Atara Biotherapeutics Files 8-K on Financials — 8-K · Mar 7, 2025
• Atara Biotherapeutics Reports Exit/Disposal Costs — 8-K · Mar 3, 2025
• Atara Biotherapeutics Files 8-K on Exit Costs — 8-K · Jan 27, 2025
• Atara Biotherapeutics Files 8-K — 8-K · Jan 21, 2025
• Atara Biotherapeutics Files 8-K — 8-K · Jan 16, 2025